Lexeo Therapeutics
LX2020
Arrhythmogenic Cardiomyopathy
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for LX2020 in Arrhythmogenic Cardiomyopathy are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06109181: Phase 2 trial, sponsor Lexeo Therapeutics, drug LX2020. Primary completion date 2026-12 (estimated).”